ReproCELL

Basic Information

Stock Code
4978
Industry
Chemicals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Kanagawa Prefecture
Establishment Year
February 2003
Listing Year
June 2013
Official Website
https://reprocell.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, Nexela Pharma, DWTI, Kids Bio, PeptiDream, Ribomic, SanBio, Helios, RenaScience, QualiPS, Takara Bio, Japan Tissue Engineering

Overview

ReproCELL is a drug discovery venture founded in 2003, a cutting-edge regenerative medicine technology company boasting a high market share centered on iPS cell-related research reagents.

Current Situation

ReproCELL recorded net sales of approximately 1.257 billion yen for the fiscal year ended March 2017, but operating profit, ordinary profit, and net profit were in the red. The mainstay iPS cell business accounts for over 90% of sales, consisting of research reagents and drug discovery support services, and holds more than 50% share in the culture medium market. In 2014, it acquired an overseas bio-venture to strengthen global expansion. It has also succeeded in the R&D of cell cryopreservation solutions, with plans for application in the regenerative medicine field going forward. Paid-in capital is approximately 5.49 billion yen, total assets are on the scale of approximately 8.4 billion yen, and there are 76 employees. It collaborates with a Shinsei Bank-affiliated venture capital firm and actively invests in iPS cell-related companies. Keys to future growth are the practical implementation in the regenerative medicine field and expansion into global markets. Risk factors include the continuation of losses and technological trends among competing bio companies. It aims to accelerate R&D and build a sustainable business foundation.

Trivia

Interesting Facts

  • Domestic top share in research reagent market utilizing iPS cell technology.
  • Founders centered on prominent professors from Kyoto University and University of Tokyo.
  • Actively invests in regenerative medicine-related ventures.
  • Built global foundation through overseas company acquisition in 2014.
  • Cell cryopreservation solutions highly evaluated both domestically and internationally.
  • Supported financially by collaboration with Shinsei Bank group company.
  • Technology and R&D focused despite 76 employees.
  • Plans market entry into regenerative medicine in the 2020s.
  • Diversifying through clinical testing outsourcing services.
  • Attractive company for applications of induced pluripotent stem cell technology.
  • Rare model involved in establishing venture capital.
  • High market share in iPS cell-related culture medium market.
  • Pursues synergy between academic research and business development.
  • One of the pioneers in iPS stem cell research in Japan.
  • Approximately 90% of sales from iPS cell-related business.

Hidden Connections

  • Strong technological collaboration with prominent professors from Kyoto University and University of Tokyo supports the management foundation.
  • Unique business model involving collaboration with Shinsei Bank-affiliated venture capital for fundraising.
  • Built international network through acquisitions of bio-ventures in the U.S. and U.K.
  • Success in iPS cell regenerative medicine field leading to expanded partnerships with pharmaceutical companies.
  • Realized diversified business model by integrating clinical testing and research reagent businesses.
  • Highly evaluated for technological strength despite relatively compact organization compared to peers.
  • Improved cryopreservation solution targeting not only domestic but also overseas markets.
  • Through venture capital establishment, invests in growth of not only itself but also related companies.

Future Outlook

Growth Drivers

  • Expansion of iPS cell research and drug discovery support markets domestically and internationally
  • New market development through regenerative medicine commercialization
  • Rapid commercialization of latest biotech
  • Promotion of utilizing global bio networks
  • Accelerated growth through strengthened venture capital collaboration
  • Customer base expansion through diversification of research reagents
  • Revenue diversification through expansion of clinical testing services
  • Technological innovation and expanded application in pharmaceutical development support
  • Tailwinds from government regenerative medicine and bio industry support policies
  • Strengthening competitive edge in global markets
  • Enhanced product value through advanced cell preservation technology
  • Increased business flexibility from bio-related regulatory easing

Strategic Goals

  • Surpass 10 billion yen in sales from iPS cell-related products and services
  • Maintain domestic top market share in regenerative medicine
  • Achieve over 50% overseas sales ratio through active global expansion
  • Establish sustainable R&D system compliant with ESG standards
  • Build growth portfolio through investments in diverse bio-ventures
  • Expand product innovation and lineup with latest technologies
  • Enhance presence in clinical testing field and create new services
  • Expand ongoing contributions to regional society and research community
  • Enrich researcher education support and talent development programs
  • Acquire international patents for new cell preservation technologies and launch in markets

Business Segments

iPS Cell-Related Research Support

Overview
Provides research reagents and equipment to support iPS cell culture, preservation, and analysis.
Competitiveness
Advanced iPS cell technology and product development through collaboration with research institutions
Customers
  • Pharmaceutical companies
  • Universities and research institutions
  • Regenerative medicine companies
  • Public research institutions
  • Biotechnology companies
Products
  • iPS cell culture medium
  • Cell cryopreservation solution
  • Cell growth factors
  • Drug discovery reagents
  • Cell analysis kits

Drug Discovery Support Services

Overview
Provides various reagents and technical services to support innovative drug discovery research.
Competitiveness
Extensive expertise and track record in drug discovery support utilizing iPS cell technology
Customers
  • Pharmaceutical companies
  • Bio-ventures
  • University spin-offs
  • Clinical trial outsourcing institutions
  • Clinical research institutions
Products
  • Drug discovery screening reagents
  • Molecular target antibodies
  • Cell-based assays
  • Drug efficacy verification support
  • Biomarker development

Clinical Testing Outsourcing Services

Overview
Offers outsourced clinical testing and clinical trial support services contributing to new drug development.
Competitiveness
High-specialty clinical testing system and knowledge in regenerative medicine
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Research institutions
  • Clinical trial outsourcing institutions
  • Public institutions
Products
  • Clinical trial outsourcing (CRO)
  • Pharmaceutical sales support (CSO)
  • Clinical trial operations outsourcing (SMO)
  • Provision of testing reagents
  • Quality management support

Competitive Advantage

Strengths

  • Over 50% domestic market share in iPS cell-related products
  • Strong technological capabilities in R&D and university collaborations
  • Diverse product lineup
  • Global expansion through acquisition of overseas venture companies
  • Financial support from Shinsei Bank group
  • Future potential in regenerative medicine
  • Proprietary cell culture and cryopreservation technologies
  • High-specialty staff organization
  • Strong partnerships with research institutions
  • Accumulated know-how in drug discovery support
  • Expansion of clinical testing outsourcing services
  • Strategic venture investments
  • Deep understanding of diverse customer segments
  • Business development capturing market niches
  • Long-term research investment stance

Competitive Advantages

  • Leading position in Japan's iPS cell culture medium market
  • Integration of global iPS cell-related assets and technologies across multiple locations
  • Collaboration with venture capital combining technology and financial strength
  • Specialized capabilities in providing drug discovery support reagents and services
  • Synergy effects from integration of clinical testing and research reagents
  • High-caliber R&D team of engineers and researchers
  • Quality management capabilities in outsourced clinical testing
  • First-mover advantage through active expansion in regenerative medicine
  • Business expansion leveraging domestic and international partnership networks
  • Risk diversification through asset diversification
  • Patents and technological superiority based on advanced cell technologies
  • Competitiveness from product portfolio diversity
  • Track record of joint research with numerous research institutions
  • Rapid technology application and conversion capabilities
  • Product development specialized for industry niche demands

Threats

  • Intensifying competition in the bio and pharmaceutical market
  • Ongoing burden of high-cost R&D
  • Risk of failing to escape loss-making operations
  • Uncertainty in regenerative medicine commercialization
  • Stricter legal regulations and ethical standards
  • Exchange rate fluctuation risks accompanying overseas market entry
  • Risk of losing patent rights or technological primacy
  • Threats from technological innovations by new entrants
  • Product obsolescence due to changing market needs
  • Risk of deteriorating fundraising environment
  • Losses from clinical trial delays or failures
  • Expansion of international competitors

Innovations

2023: Acquisition of U.S. StemGent Inc.'s iPS Cell Business Division

Overview
Acquired the iPS cell-related business of U.S. bio-venture StemGent, expanding global assets.
Impact
Contributes to internationalization of research foundation and strengthening of product lineup

2022: Release of improved cell cryopreservation solution product

Overview
Commercialized a new version of cryopreservation solution with enhanced cell damage suppression function.
Impact
Improves customer satisfaction and market competitiveness

2021: Introduction of iPS cell culture medium automated manufacturing system

Overview
Introduced latest automation equipment to improve production efficiency and quality stability.
Impact
Achieves production cost reduction and shortened delivery times

2020: Development of high-sensitivity technology for drug discovery support fluorescent labeling reagents

Overview
Developed technology that significantly improves sensitivity through enhancement of fluorescent labeling technology.
Impact
Improves drug discovery efficiency and expands customer base

Sustainability

  • Resource-saving and harmless processes in cell culture
  • Adoption of recyclable packaging materials
  • Introduction of waste reduction programs
  • Reduction of medical resources through regenerative medicine technology
  • Strict adherence to ethical standards in research activities